Drug Search Results
More Filters [+]

Encorafenib

Alternative Names: encorafenib, lgx818, braftovi
Latest Update: 2024-12-07
Latest Update Note: Clinical Trial Update

Product Description

Encorafenib is used along with binimetinib (Mektovi) to treat certain types of melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be removed by surgery. It is also used with cetuximab (Erbitux) to treat a certain type of colon cancer in adults that has spread to other parts of the body after other treatment(s). Encorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a618040.html)

Mechanisms of Action: BRAF Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Croatia | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States

Approved Indications: Colorectal Cancer | Melanoma | Oncology Solid Tumor Unspecified | Oncology Unspecified

Known Adverse Events: Abdominal Pain | Pain Unspecified | Dermatitis | Arthralgia | Melanoma | Diarrhea

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Encorafenib

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 57

Highest Development Phases

Phase 3: Biliary Tract Cancer|Colorectal Cancer|Melanoma

Phase 2: Adenocarcinoma|Brain Cancer|Multiple Myeloma|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Thyroid Cancer

Phase 1: Healthy Volunteers|Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2021-004310-19

P3

Active, not recruiting

Melanoma

2035-04-19

2021-000743-41

P3

Active, not recruiting

Melanoma

2035-01-21

The STARBOARD Study

P3

Active, not recruiting

Melanoma

2030-06-29

BEPCOME-MB

P2

Active, not recruiting

Melanoma

2030-01-13

Recent News Events